Home » Healthcare » Pharmaceuticals » Multiple Drug Resistance Bacterial Infection Treatment Market

Multiple Drug Resistance Bacterial Infection Treatment Market By Vector (Critical, Medium, High), By Drug Class (Cephalosporin, Beta Lactam, Beta Lactamase Inhibitors, Oxazolidinone, Cyclic Lipopeptide, Glycolipopeptides ) – Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Price: $4999

Published: | Report ID: 14264 | Report Format : PDF

Market Insights

This report on the global multiple drug resistance bacterial infection treatment market studies various vectors and drug classes. The rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market’s growth. The limiting factors related to this market are the complex regulatory approvals for antibiotics, which vary according to country. A promising pipeline of novel antibiotics with more effective mechanisms of action to counteract drug resistance by microbes will result in deep market penetration of the multiple drug resistance bacterial infection treatment market.

For the purpose of this study, the vectors studied include critical, high, and medium; the drug classes studied for the purpose of this research are segmented as cephalosporins, beta-lactams, beta-lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides, and others. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The global multiple drug resistance bacterial infection treatment market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets.

The regions are also further sub-segmented on the basis of major countries:

  • North America
    • US.
    • Canada
  • Europe
    • Germany
    • France
    • UK.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study.

Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, and Zavante Therapeutics, Inc.

Based on drug class, the multiple drug-resistance bacterial infection treatment markets are categorized into

Cephalosporin

  • Cefixime (3rd Generation)
  • Ceftriaxone (3rd Generation)
  • Ceftobiprole (5th Generation)
  • Beta-Lactam
  • Doripenem
  • Imipenem
  • Meropenem
  • Ceftazidime
  • Beta-lactamase inhibitors
  • Sulbactam
  • Tazobactum
  • Avibactum
  • Clavam
  • Oxazolidinone
  • Linezolid
  • Cyclic Lipopeptide
  • Daptomycin
  • Glycolipopetides
  • Dalbavancin
  • Vancomycin

Others

  • Polymixins
  • Tetracycline and Derivatives
  • Penicillins
  • Macrolides
  • Macrolide-Lincosamide-Streptogramin
  • Rifamycins
  • Fluoroquinolones
  • Nitroimidazole
  • Potassium Bismuth Subcitrate

Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control. According to World Health Organization (WHO) 2015 awareness guidelines, in order to prevent and control antibiotic resistance, use only the prescribed antibiotics, never share or use leftover antibiotics, and prevent infection by practicing safe sex, maintaining personal hygiene, consuming hygienic food and water, and staying up to date on vaccinations.

The factors responsible for the growth of the multiple drug resistance bacterial infection treatment market are the rising prevalence of antibiotic resistance and a promising pipeline to counteract existing drug resistance. Because of factors such as the rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa carbapenem resistance and the broad spectrum activity provided by beta-lactam drugs such as ceftazidime-avibactam and doripenem, beta-lactam drugs dominated the market in 2016.

Oxazolidinone and glycolipopeptides will be the fastest-growing segments throughout the forecast period of 2017–2025, primarily due to factors such as an increasing patient pool suffering from Enterococcus faecium and Staphylococcus aureus, methicillin and vancomycin resistance, and improved pharmacodynamic activity shown by drugs such as Linezolid and Dalbavancin.

Overall, the global multiple drug resistance bacterial infection treatment market is highly competitive with the presence of multiple players like Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., etc., Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the number of novel antibiotics to counteract drug resistance and improve pharmacokinetics for better patient compliance and low cost.

Based on vector, the global multiple drug resistance bacterial infection treatment market is categorized into

Critical

  • Acinetobacter baumannii (resistant to carbapenems)
  • Pseudomonas aeruginosa (resistant to carbapenem)
  • Carbapenem-resistant Enterobacteriaceae

High

  • Enterococcus faecium (Vancomycin-Resistant)
  • (Clarithromycin-Resistant) Helicobacter pylori
  • Staphylococcus aureus (methicillin-resistant, vancomycin-intermediate, and resistant)
  • Neisseria gonorrhea (Fluoroquinolone-Resistant, Cephalosporin-Resistant)

Medium

  • Streptococcus pneumonia (penicillin-non-Susceptible)
  • Haemophilus influenza (ampicillin-resistant)
  • Shigella spp. (fluoroquinolone-resistant)
  • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

According to the Department of Health and Human Services Assistant Secretary for Preparedness and Response (ASPR) 2015 report, there have been 15 corporate entries and 36 corporate exits involved in antimicrobial treatment over the last 15 years. In 2016, the critical vector segment held the largest market in the multiple drug resistance bacterial infection treatment market, chiefly due to factors such as the rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases and the lack of novel drug launches in the beta-lactam antibiotics.

This will serve as a great opportunity for budding industries to reclaim new grounds to fortify their product portfolio. The high segment will be the fastest growing market throughout the forecast period 2017-2025 due to the extensive growth in Helicobacter pylori (clarithromycin-resistant) and Staphylococcus aureus (methicillin-resistant, vancomycin-intermediate, and resistant) infections and the recent launch of novel drug formulations. Pylera is used to overcome clarithromycin resistance in peptic ulcer treatment; drugs such as linezolid, daptomycin, and dalbavancin have an effective mechanism of action in comparison to vancomycin in the treatment of antibiotic resistance.

In 2016, North America was identified as the largest market for multiple drug resistance bacterial infection treatment. According to the Department of Health and Human Services 2015 CDC report, approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly to the rising prevalence of multiple drug resistance cases, evolved health infrastructure, and affordable reimbursement scenarios. According to the European Centre for Disease Prevention and Control, approximately 25,000 deaths were associated with multidrug-resistant bacterial infection; the growth is chiefly attributed to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment and supportive regulatory approval for the launch of new antibiotics for the treatment of multiple drug resistance.

Asia Pacific will be the fastest-growing regional segment throughout the forecast period of 2017–2025. The growth is attributed to factors like the rising prevalence of geriatric populations suffering from multiple drug-resistant bacterial infections and increasing disposable income in these regions. Factors such as developing health infrastructure and increasing awareness regarding the judicious use of prescribed antibiotics, especially in remote areas, are going to fuel the rapid growth of the multiple drug resistance bacterial infection treatment market in Latin America, the Middle East, and Africa in the near future.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Multiple Drug Resistance Bacterial Infection Treatment Market Portraiture
2.1.1. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2016
2.1.2. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2016
2.1.3. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2016

Chapter 3. Multiple Drug Resistance Bacterial Infection Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Prevalence Data of Major Target Diseases
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Porter’s Five Forces Analysis
3.7. Attractive Investment Proposition, by Geography
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector
4.3. Critical
4.3.1. Acinetobacter baumanni (Carbapenem-Resistant)
4.3.2. Pseudomonas aeruginosa (Carbapenem-Resistant)
4.3.3. Enterobacteriaceae (Carbapenem-Resistant)
4.4. Medium
4.4.1. Enterococcus faecium (Vancomycin-Resistant)
4.4.2. Helicobacter pylori (Clarithromycin-Resistant)
4.4.3. Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)
4.4.4. Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)
4.5. High
4.5.1. Streptococcus pneumonia (Penicillin-Non-Susceptible)
4.5.2. Haemophilus influenza (Ampicillin-Resistant)
4.5.3. Shigella spp. (Fluoroquinolone-Resistant)
4.5.4. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

Chapter 5. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class
5.2. Cephalosporin
5.2.1. Cefixime (3rd Generation)
5.2.2. Ceftriaxone (3rd Generation
5.2.3. Ceftobiprole (5th Generation)
5.3. Beta Lactam
5.3.1. Doripenem
5.3.2. Imipenem
5.3.3. Meropenem
5.3.4. Ceftazidime
5.4. Beta Lactamase Inhibitors
5.4.1. Sulbactam
5.4.2. Tazobactum
5.4.3. Avibactum
5.4.4. Clavam
5.5. Oxazolidinone
5.5.1. Linezolid
5.6. Cyclic Lipopeptide
5.6.1. Daptomycin
5.7. Glycolipopeptides
5.7.1. Dalbavancin
5.7.2. Vancomycin
5.8. Others
5.8.1. Polymixins
5.8.2. Tetracycline and Derivatives
5.8.3. Penicillins
5.8.4. Macrolides
5.8.5. Macrolide-Lincosamide-Streptogramin
5.8.6. Rifamycins
5.8.7. Fluoroquinolones
5.8.8. Nitroimidazole
5.8.9. Bismuth Subcitrate Potassium

Chapter 6. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.2.1. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.2.2. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.3. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.3.1. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.3.2. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.3. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. France
6.3.3.4. Rest of Europe
6.4. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.5.1. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.6.1. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.6.2. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.3. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Vector Portfolio
7.1.4. Key Developments
7.2. Actelion Pharmaceuticals Ltd.
7.3. Albany Molecular Research, Inc.
7.4. Allergan plc.
7.5. AstraZeneca
7.6. Bayer AG
7.7. Biocon
7.8. Daiichi Sankyo Company
7.9. GlaxoSmithKline plc.
7.10. Macrolide Pharmaceuticals, Inc.
7.11. Merck & Co, Inc.
7.12. Pfizer, Inc.
7.13. Sanofi
7.14. Teva Pharmaceuticals Industries Ltd.
7.15. Wockhardt
7.16. Zavante Therapeutics, Inc.
7.17. Other Notable Players

List of Figures

FIG. 1 Multiple Drug Resistance Bacterial Infection Treatment Market: Segmentation
FIG. 2 Global Multiple Drug Resistance Bacterial Infection Treatment Market Share, by Vector, 2016 (Value %)
FIG. 3 Global Multiple Drug Resistance Bacterial Infection Treatment Market Share, by Drug Class, 2016 (Value %)
FIG. 4 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Acinetobacter baumanni Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Pseudomonas aeruginosa Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Enterobacteriaceae Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Enterococcuc faecium Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Helicobacter pylori Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Staphylococcus aureus Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Neisseria gonorrhea Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Steptococcus pneumonia Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Haemophilus influenza Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Shigella spp. Market, 2015 – 2025 (US$ Mn)
FIG. 17 Global Clostridium difficile Market, 2015 – 2025 (US$ Mn)
FIG. 18 Global Cefixime Market, 2015 – 2025 (US$ Mn)
FIG. 19 Global Ceftriaxone Market, 2015 – 2025 (US$ Mn)
FIG. 20 Global Ceftobiprole Market, 2015 – 2025 (US$ Mn)
FIG. 21 Global Doripenem Market, 2015 – 2025 (US$ Mn)
FIG. 22 Global Imipenem Market, 2015 – 2025 (US$ Mn)
FIG. 23 Global Meropenem Market, 2015 – 2025 (US$ Mn)
FIG. 24 Global Ceftazidime Market, 2015 – 2025 (US$ Mn)
FIG. 25 Global Sulbactam Market, 2015 – 2025 (US$ Mn)
FIG. 26 Global Tazobactam Market 2015 – 2025 (US$ Mn)
FIG. 27 Global Avibactam Market, 2015 – 2025 (US$ Mn)
FIG. 28 Global Clavam Market, 2015 – 2025 (US$ Mn)
FIG. 29 Global Linezolid Market, 2015 – 2025 (US$ Mn)
FIG. 30 Global Daptomycin Market, 2015 – 2025 (US$ Mn)
FIG. 31 Global Dalbavancin Market, 2015 – 2025 (US$ Mn)
FIG. 32 Global Vancomycin Market, 2015 – 2025 (US$ Mn)
FIG. 33 Global Others Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 34 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 35 Canada Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 36 U.K. Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 37 Germany Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 38 France Multiple Drug Resistance Bacterial Infection Treatment Market, 2015-2025 (US$ Mn)
FIG. 39 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 40 Japan Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 41 China Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 42 India Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 43 Rest of Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 44 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 45 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 46 Rest of Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 47 GCC Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 48 Rest of Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 2 Global Critical Vector Market, 2015 – 2025 (US$ Mn)
TABLE 3 Global High Vector Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Medium Vector Market, 2015 – 2025 (US$ Mn)
TABLE 5 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Global Cephalosporin Market, 2015 – 2025 (US$ Mn)
TABLE 7 Global Beta Lactam Market, 2015 – 2025 (US$ Mn)
TABLE 8 Global Beta Lactamase Inhibitors Market, 2015 – 2025 (US$ Mn)
TABLE 9 Global Oxazolidinone Market, 2015 – 2025 (US$ Mn)
TABLE 10 Global Cyclic Lipopeptide Market, 2015 – 2025 (US$ Mn)
TABLE 11 Global Glycolipopeptides Market, 2015 – 2025 (US$ Mn)
TABLE 12 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 13 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 14 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 15 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 16 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 17 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 18 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 19 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 20 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 21 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 22 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 23 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 24 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 25 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 26 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 27 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 28 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 29 Actelion Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 30 Albany Molecular Research, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 31 Allergan plc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 32 AstraZeneca: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 33
TABLE 34 Bayer AG: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 35 Biocon: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 36 Daiichi Sankyo Company: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 37 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 38 Macrolide Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 39 Merck & Co, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 40 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 41 Sanofi: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 42 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 43 Wockhardt: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 44 Zavante Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Multiple Drug Resistance Bacterial Infection Treatment Market?

The market for Multiple Drug Resistance Bacterial Infection Treatment Market is expected to reach USD$ 44,060.77 Mn in 2025.

What is the Multiple Drug Resistance Bacterial Infection Treatment Market CAGR?

The Multiple Drug Resistance Bacterial Infection Treatment Market is expected to see significant CAGR growth over the coming years, at 6.01 %.

What is the Forecast period considered for Multiple Drug Resistance Bacterial Infection Treatment Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Multiple Drug Resistance Bacterial Infection Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc. are some of the major players in the global market.

Prostate Cancer Market

Published:
Report ID: 36273

Antineoplastic Agents Market

Published:
Report ID: 36065

US Retail Pharmacy Market

Published:
Report ID: 32801

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN